Načítá se...
NEW AND EMERGING DEVELOPMENTS IN EXTENSIVE STAGE SMALL CELL LUNG CANCER THERAPEUTICS
PURPOSE OF REVIEW: Extensive-stage small cell lung cancer (SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8–10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based...
Uloženo v:
| Vydáno v: | Curr Opin Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5139911/ https://ncbi.nlm.nih.gov/pubmed/26844984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0000000000000264 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|